liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Phase II Study of Docetaxel Weekly in Combination With Carboplatin Every 3 Weeks as First-Line Chemotherapy in Stage IIB to Stage IV Epithelial Ovarian Cancer
University Hospital, Örebro.
University Hospital, Örebro.
Sahlgrenska University Hospital.
Sahlgrenska University Hospital.
Show others and affiliations
2012 (English)In: International Journal of Gynecological Cancer, ISSN 1048-891X, E-ISSN 1525-1438, Vol. 22, no 1, 47-53 p.Article in journal (Refereed) Published
Abstract [en]

Objectives: The purpose of this study was to assess the response rate, toxicity, progression-free survival, and overall survival in a series of patients with advanced-stage ovarian carcinoma treated with a first-line weekly docetaxel and 3 weekly carboplatin regimen. less thanbrgreater than less thanbrgreater thanMethods: All eligible patients were treated with intravenous docetaxel (30 mg/m(2)) on days 1, 8, and 15, and carboplatin (area under the curve, 5) on day 1; every 21 days for at least 6 cycles. less thanbrgreater than less thanbrgreater thanResults: One hundred six patients received at least one cycle of primary chemotherapy (median, 6.0; range, 1-9), and they were evaluable for toxicity assessment. Eighty-five patients had evaluable (measurable) disease and received at least 3 courses of chemotherapy and were evaluable for clinical response rate. The overall response rate was 78.8% (95% confidence interval, 70.1%-87.5%), and the biochemical response 92.8% (95% confidence interval, 87.2%-98.4%). The median progression-free survival was 12.0 months and the median overall survival was 35.3 months. Thirty-six patients (34.0%) experienced grades 3 and 4 neutropenia, which resulted in the removal of 3 patients. Six patients (5.7%) experienced grades 3 or 4 thrombocytopenia. No patients experienced grade 3 to grade 4 sensory neuropathy. Epiphora, nail changes, and fatigue were frequently recorded nonhematologic adverse effects. less thanbrgreater than less thanbrgreater thanConclusions: The tolerable hematologic toxicity (no need for colony-stimulating factors) and the low rate of neurotoxicity (only grades 1-2) and response rates in line with the standard 3-week paclitaxel-carboplatin regimen for advanced primary ovarian carcinoma after suboptimal cytoreductive surgerymake this regimen an interesting alternative in selected patients.

Place, publisher, year, edition, pages
Lippincott, Williams and Wilkins / Wiley-Blackwell , 2012. Vol. 22, no 1, 47-53 p.
Keyword [en]
Ovarian cancer, Docetaxel, Carboplatin, Weekly administration
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-74431DOI: 10.1097/IGC.0b013e318234fa3aISI: 000298628800011OAI: diva2:484427
Funding Agencies|Sanofi-Aventis AB, Stockholm, Sweden||Available from: 2012-01-27 Created: 2012-01-27 Last updated: 2012-02-06

Open Access in DiVA

No full text

Other links

Publisher's full text
By organisation
Department of Oncology UHL
In the same journal
International Journal of Gynecological Cancer
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 20 hits
ReferencesLink to record
Permanent link

Direct link